Some cancer therapies damage DNA and cause mutations in both cancerous and healthy cells. Therapy-induced mutations may underlie some of the long-term and late side effects of treatments, such as mental disabilities, organ toxicity and secondary neoplasms. Nevertheless, the burden of mutation contributed by different chemotherapies has not been explored. Here we identify the mutational signatures or footprints of six widely used anticancer therapies across more than 3,500 metastatic tumors originating from different organs. These include previously known and new mutational signatures generated by platinum-based drugs as well as a previously unknown signature of nucleoside metabolic inhibitors. Exploiting these mutational footprints, we estimate the contribution of different treatments to the mutation burden of tumors and their risk of contributing coding and potential driver mutations in the genome. The mutational footprints identified here allow for precise assessment of the mutational risk of different cancer therapies to understand their long-term side effects.
T umors initiate and evolve as a result of the interplay between somatic mutations and selective constraints faced throughout their development 1 . All cells accumulate somatic variants that arise from both endogenous and external mutational processes. Each of these processes preferentially contributes certain types of nucleotide changes in specific sequence contexts. Thus, the repertoire of somatic mutations a cell has acquired can be used to identify mutational signatures, which represent the mutational processes that have been active throughout its history [2] [3] [4] [5] [6] [7] .
Many chemotherapies, which are still the main pharmacological treatment for primary tumors, cause DNA damage or change the pool of nucleotides; hence, they target both cancerous and noncancerous cells. While many cancerous and healthy cells affected by the DNA damage generated by these drugs die, others survive. In the progeny of surviving cells, at least part of the original damage will be converted into mutations (Fig. 1a ). Therefore, chemotherapies may contribute mutations to the tumor as well as the healthy tissues of the patient; this probably underpins some of the long-term secondary effects caused by these treatments [8] [9] [10] . As with other mutational processes, nucleotide changes caused by chemotherapy agents leave an imprint in the genomes of exposed cells, which can be detected as specific mutational signatures. Indeed, platinum-based drugs 6, 7, 11, 12 , temozolomide (TMZ) 2, 13 and radiation treatments 14 have already been associated with specific mutational signatures; for some of these treatments, the mutational footprints have been confirmed experimentally 6 . However, virtually nothing is known about the effects of other chemotherapy treatments on the mutational pattern of somatic and germ cells, since mutational signatures have been studied mainly across primary chemotherapy-naive tumors. As a result, current research still ignores the specific mutational profile and burden caused by most chemotherapies in the cells of patients. This is of crucial importance to understand the resistance of tumors to chemotherapies and explain and predict the long-term effects of these treatments. In the present study, using the somatic mutations present in 3,506 metastatic tumors, we identify the mutational footprints left by six anticancer therapies (five chemotherapy agents and radiotherapy). Using these specific footprints, we then estimate the contribution of the chemotherapies to the mutational burden of these tumors, comparing them to the endogenous mutations contributed by the natural aging process. Finally, we assess the risk posed by each of these therapies in terms of generating coding mutations and potentially cancer driver mutations. We regard these two measures as the 'mutational toxicity' of these chemotherapy agents in different tissues.
Results
Mutational signatures associated with anticancer therapies. We reasoned that the analysis of available metastases of patients who have undergone anticancer treatment regimens provides a good opportunity to identify the mutational footprint of these agents. Treatment-induced mutations occur independently across cells in a tissue after treatment. Therefore, they are private to each surviving cell; thus, their variant allele frequency (VAF) falls below the detection limit of bulk sequencing. However, some of these tumor cells exposed to treatment experience clonal expansion; as a result in the metastases, treatment-induced mutations may be detectable through bulk sequencing ( Fig. 1a ). We analyzed a cohort of 3,506 metastatic tumor samples sequenced at the whole-genome level 15 . These samples were taken from patients who previously had primary tumors originating from 31 known different organs/tissues ( Fig. 1b and Supplementary Table 1 ). We used SignatureAnalyzer (v.4) 16, 17 and SigProfiler (v.2.3) 2,18 , two widely employed methods based on different principles that address nonnegative matrix factorization (NMF) and a third non-NMF method 19 (across tumors of colorectal origin), to extract mutational signatures active across these metastatic samples (see Methods). Mutational signatures of single-base substitutions (SBS), double-base substitutions (DBS) and indels were extracted separately ( Fig. 1c and Supplementary Note). Some of the signatures discovered in the tumors of this metastatic cohort have been identified previously [2] [3] [4] 6, 18, 20, 21 ; thus, to refer to them, we employ their known etiologies (for example, aging signature).
We manually curated the treatment information for all the patients under study. In this cohort, 2,124 tumor samples were taken from patients whose treatment consisted of 1 or more of 206 drugs from 58 distinct Food and Drug Administration (FDA) classes ( Fig.  2a ). These drugs were administered to patients for a median of 2.33 years before obtaining the biopsies of the metastases (Extended Data Fig. 1a ). Platinum-based drugs (cisplatin, oxaliplatin and carboplatin) were the class most frequently used to treat the patients in the cohort. The choice of chemotherapy was primarily guided by the organ of origin of the tumors; most patients (1, 848 ) received more than one drug in the course of their treatment, either in a combined or sequential regimen ( Fig. 2a and Extended Data Fig. 1b ).
To distinguish mutational signatures among those identified in this cohort that constitute the footprint of chemotherapies, we designed an ad hoc logistic ensemble regression model (henceforth regression model). This model identifies associations between the exposure of metastatic tumors in the cohort to chemotherapy treatments and the activity of the identified mutational signatures ( Fig. 2b and Extended Data Fig. 2a-c) . It controls for potential associations between treatments and the organs of origin of the tumors, and reliably identifies signatures associated with the treatments, as demonstrated in mutations injected in samples of synthetic datasets (Supplementary Note). The approach also controls for potential spurious associations due to simultaneous treatments with several drugs, for example, a signature that appears to be related to bevacizumab, but which is actually associated with concomitant oxaliplatin. We ran pan-cancer and organ-specific regressions to gain sensitivity in identifying potential associations missed across the entire cohort due to dilution effects. As a result (Fig. 2c) , we identified seven mutational signatures extracted with SignatureAnalyzer (five SBS signatures and two DBS signatures) associated with four treatments with a pan-cancer or organ-specific effect size > 2 and P < 0.001 (see Methods). Interestingly, the set of SigProfilerextracted signatures that are significantly associated with treatments is very similar. Often, two signatures extracted as independent by one method appear as a single signature according to the other ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG CT  GA  GG  GT  TA  TG  TT  CA  CC  CG  GA  GC  TA  AA  AG  AT  GA  GG  GT  TA  TG  TT  AT  GC  GT  TA  TC  TT  AA  AC  AG  GA  GC  GG  TA  TC  TG  AA  AG  AT  CA  CG  TA  AT  CG  CT  GC  GG  GT  AA  AG  AT  CA  CG  CT  GA  GG  GT  AA  AC  AT  CA  CC  CT  GA  GC  GT  AA  AC  AG  CA  CC  CG  GA  GC Surviving cells harbor treatment-induced mutations caused by unrepaired DNA damage, the consequences of misincorporated nucleotide analogs or introduced by error-prone polymerases during repair. These treatment mutations are private to each surviving cell after the first round of replication, have low VAF and are undetectable through bulk sequencing. Pretreatment mutations are present at higher VAF. Some surviving cells may grow faster than their neighbors to occupy the space opened by the large-scale death of tumor cells. Over time, these faster-growing cells will undergo clonal expansion and their progeny will represent a larger fraction of the population, effectively amplifying their genetic material within the tumor pool. At the time of biopsy of the metastasis, the VAF of treatment mutations present in the original surviving cells may be higher than the threshold of detection of bulk sequencing. b, Composition of the metastatic cohort in terms of organ of origin of the primary tumor. The color coding of the organs of origin is used in subsequent figures. c, Example SBS, DBS and short-indel signatures extracted from the metastatic cohort using SignatureAnalyzer. The profiles of the signatures identified using both methods appear in the Supplementary Note and Supplementary Data. method (Extended Data Fig. 3a-c) . Overall, the chemotherapy mutational footprints detected were robust to the singularities of different signature extraction methods (Extended Data Fig. 3a -c, Supplementary Note and Supplementary Data).
Mutational footprints of six anticancer therapies. Four SBS and two DBS signatures constituted the footprint of three platinumbased drugs ( Fig. 3a and Extended Data Figs. 2b,c and 3a,b), with two SBS signatures associated with more than one drug and both DBS signatures associated with the three platinum-based drugs. One signature had been identified previously as the footprint of the treatment with cisplatin or carboplatin (with cosine similarity 0.954) 6 . However, an oxaliplatin-related SBS signature was detected in this cohort for the first time, with slight differences between the profiles identified by SignatureAnalyzer and SigProfiler. Interestingly, in colorectal tumors, an oxaliplatin-related signature virtually identical to that identified using SignatureAnalyzer was extracted by a third independent method (hierarchical Dirichlet process; Extended Data Fig. 3c ). Platinum based-drug-associated signatures exhibit transcriptional strand asymmetry (see Methods), that is, lower activity in the template strand of transcribed genes (Extended Data Fig. 2c ). These drugs generate DNA adducts that cause RNA polymerases to stall and recruit the transcription-coupled nucleotide excision repair 22, 23 machinery, yielding the asymmetric activity of its mutational footprint between strands. One known indel signature (ID12 in the Supplementary Note; previously identified as ID6) associated with radiation treatment 14 was close to significance (P < 0.01, effect size < 2). Its activity was higher in homologous-recombination-defective than homologous-recombination-proficient tumors (Extended Data Fig. 4a ). Both homologous-recombination-proficient and homologousrecombination-deficient irradiated tumors exhibit significantly higher activity of the irradiation signature than corresponding nonirradiated ones, although differences are larger across homologous-recombination-proficient tumors. The regression model was also unable to detect a known SBS signature associated with TMZ treatment 2, 13 . We searched specifically for this signature and found it active in five TMZ-exposed samples, but lacking in 17 equally TMZ-treated tumors, thus making the association given by the regression model nonsignificant (Extended Data Fig. 4b , left panel). Previous studies have associated the burden of TMZ-related mutations with the presence of mismatch repair (MMR) inactivating mutations in tumors 13 . We then searched for such mutations and found them in the 5 tumors with TMZ signature activity, but not in the 17 other TMZ-exposed samples. However, four MMRdeficient tumors with no annotated TMZ treatment showed a relatively high activity of the TMZ-associated signature, indicating that their treatment data may be incomplete. These results, which were validated in an independent cohort of whole-exome glioblastomas (Extended Data Fig. 4b , right panel) corroborate the importance of MMR deficiency in detecting the activity of the TMZ-related signature.
We also discovered a previously unknown SBS signature significantly associated with treatment with two nucleoside metabolic inhibitors: capecitabine and fluorouracil (5-FU), a product of the metabolic degradation of the former ( Fig. 3b and Extended Data Fig. 5a ,b). A previous survey of chemically induced mutational signatures failed to detect one associated with 5-FU, probably due to low doses 24 . In the present study, to obtain experimental validation of the association of capecitabine/5-FU with this signature, we analyzed mutations in five resistant cultures of Leishmania infantum exposed to 5-FU 25 . This showed a profile dominated by CTC>CGC and CTT>CGT mutations, very similar to that of the SBS capecitabine signature (cosine similarity of 0.8; P < 0.001; Fig. 3c and Extended Data Fig. 5c ), confirming the etiology of the signature identified in tumors. In cells, 5-FU is converted to 5-fluorodeoxyuridine monophosphate, an inhibitor of thymidylate synthase, and 5-fluorodeoxyuridine triphosphate. As a result, the pool of nucleotides is acutely depleted for thymidine triphosphate and enriched for 5-fluorodeoxyuridine triphosphate, which polymerases could incorporate into the DNA 26, 27 . The capecitabine/5-FU signature exhibits a mutational profile very similar to signature 17b (cosine similarity of 0.97), probably caused by oxidative damage to DNA bases in certain tissues, such as the esophagus 28 . Both the capecitabine/5-FU and the 17b signatures coexisted in the tumors of the cohort according to the three methods of signature extraction used (Extended Data Fig. 3c ). Nevertheless, while the previously reported 17b signature is active across gastric and esophageal cancers, the SBS capecitabine/5-FU signature is detectable only in tumors exposed to the drugs (Extended Data Fig. 5d ).
Characteristics of therapy-associated mutations.
We hypothesized that, since treatment-associated signatures appear only as a consequence of the exposure to chemotherapy treatments, that is, relatively late in the evolution of tumors ( Fig. 1a and Extended Data Fig. 6a ), they should exhibit specific properties that differ from those contributed by many endogenous mutational processes. Thus, we calculated the relative time of appearance of clonal SBS across the 3,506 tumor samples 29 in the adult metastatic cohort, and classified them in each tumor as 'clonal early' or 'clonal late' . Then, for each tumor we calculated the enrichment for late variants (late-to-early clonal mutation fold change) in the SBS contributed by each signature. As predicted, the SBS contributed by treatmentassociated signatures were enriched for late variants relative to those contributed by signatures that are active only early on or throughout the evolution of tumors ( Fig. 4a and Extended Data Fig. 6b ). Mutations contributed by drug-associated signatures also tend to be subclonal ( Fig. 4b and Extended Data Fig. 6c ). This is consistent with treatment-associated mutations being late and occurring randomly across tumor cells, and several surviving tumor cells giving rise to different clones of the metastases (Fig. 1a ). treatments administered to donors in the metastatic cohort, grouped by organ of origin of the primary and FDA family. Right: stacked bar plots of the number of metastatic tumors exposed to the two example drugs. Due to complex regimens, the donor therapy pairs counted add up to more than the total number of tumors in panel b. EGFR, epidermal growth factor receptor; GRHR, gonadotropin-releasing hormone receptor; HER2, human epidermal growth factor receptor 2; PD-1, programmed cell death protein 1; VEGF, vascular endothelial growth factor b, Schematic representation of the ensemble regression model (see Methods). Tumors from different organs (colors shown immediately above the heatmap) may be exposed or unexposed to a treatment (X). One thousand balanced subsets of tumors exposed and unexposed to X were randomly sampled from this matrix stratified by organ of origin and then classified using logistic regression. The effect size of the regression model for each signature was calculated as the fold change between the mean exposure of treated and untreated tumors. The results are filtered to discard spurious associations explained by cotreatment regimens. c, Treatment-associated mutational signatures (extracted with SignatureAnalyzer). Each dot represents one of the 7,465 signature treatment pairs tested. Associations deemed significant (effect size > 2 and P < 0.001) not explained by cotreatment are highlighted. Associations were detected using organ-specific regressions or by analyzing the entire metastatic cohort. The carboplatin-associated signature in ovarian cancer and the capecitabine-associated signature in colorectal cancer are 'rescued', since they are very close to significance (P = 0.001) and detected in the pancancer analysis. Full results are shown in Supplementary Furthermore, we reasoned that more mutations contributed by drug-associated signatures should appear in metastatic tumors from patients who have been under treatment for longer periods or who have received more courses of treatment. We calculated the duration of the overall period of exposure to a drug of the tumor samples taken from patients exposed to platinum-based drugs or capecitabine/5-FU as the difference between the annotated start and end dates of treatment. The quartile of tumors with the longest period of exposure to therapies exhibited a significantly higher mutational burden (SBS and DBS) contributed by treatment-associated signatures than the quartile of tumors with the shortest period of exposure ( Fig. 4c and Extended Data Fig. 6d,e ). In contrast, the number of mutations contributed by the aging signature did not differ between the shortand long-term exposure tumor samples (Extended Data Fig. 6f Taken together, these observations provide further supporting evidence of the causal association between treatments and the mutational signatures described earlier.
Mutational burden in metastatic tumors contributed by chemotherapy.
Chemotherapy agents such as platinum-based drugs and capecitabine/5-FU have the potential to cause mutations in both tumor and healthy cells. We reasoned that the identification of their mutational footprints described earlier provides an opportunity to estimate their mutational contribution to metastatic tumors of different origins, which constitutes a proxy of their mutational toxicity for healthy tissues (see Discussion).
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exposed to treatments during a comparatively short period of time, they are exposed to aging mutations much longer. Chemotherapies induce about 100 times more mutations than the aging signature during the same period of exposure ( Fig. 6a , Extended Data Figs. 8d,h, 9d,h and 10a,b and Supplementary Table 1 ).
The risk of coding mutations posed by therapies. The mutational toxicity of chemotherapies can also be estimated through their risk of causing coding mutations or specifically mutations affecting cancer genes. We reasoned that different mutational processes (by virtue of their different mutational profiles and activity across DNA strands and genomic regions) may pose different risks of contributing coding mutations. Thus, we used the contribution of different therapies to the TMB to estimate their risk of causing coding mutations and mutations in cancer genes 31 in the cells of patients. First, the activity of a signature across the human genome was used to calculate a linear relationship between the number of mutations that the signature contributes and the expected number of coding mutations, accounting for its mutational profile and its differential rate along the genome (see Methods). For instance, we calculated that 33.53 out of 1,000 mutations contributed by the aging signature across tumors of colorectal origin are expected to affect the sequence of coding genes, and 1.47 are expected to affect the sequence of known cancer genes (Fig. 6b ). However, out of 1,000 oxaliplatin-contributed mutations, only 12.27 are expected to affect the sequence of coding genes and 0.6 to affect that of known cancer genes (Fig. 6b ). Then, we calculated the actual risk posed by chemotherapy treatments by interpolating the number of treatment-associated mutations observed across tumors (given their period of exposure to chemotherapy) within the linear relationship described earlier ( Fig. 6c and Extended Data Fig. 10c-e ).
Thus, we determined that tumors originating in the colon or rectum exposed to oxaliplatin for 21 weeks (the median duration of the period of exposure observed for colorectal tumors in the cohort) are at risk of receiving close to 20 coding-affecting mutations and 1 mutation affecting a cancer gene ( Fig. 6c and Extended Data Fig. 10e,f) . However, during the same period, less than 1 coding-affecting mutation and less than 0.01 mutations affecting cancer genes are contributed by the aging process ( Fig. 6c and Extended Data Fig. 10c-f ).
Discussion
The short-term side effects of some chemotherapies are characterized by the death of healthy cells, which is triggered by toxic levels of damage to their DNA [32] [33] [34] [35] [36] . While the loss of healthy cells may also underlie some longer-term side effects, somatic mutations that result from DNA damage across tissues probably also contribute to some adverse effects, such as the emergence of secondary malignancies [37] [38] [39] . This is important for cancer survivors, children in particular, who could develop these long-term adverse effects even decades after their initial diagnosis and treatment.
In the present study, we estimated the mutational toxicity of three platinum-based drugs and capecitabine using their identified mutational footprint across metastatic tumors. Most of the mutational footprints identified in this metastatic cohort associated with these drugs have been validated by other studies 2, 3, 6, 7, [12] [13] [14] or shown in this study (capecitabine/5-FU). Slight differences in the profile of mutational signatures identified using different extraction methods were observed. Often, a mutational signature associated with a treatment was split into several profiles by one of the methods used. Nevertheless, by pooling together all signatures associated with a drug and focusing on tumors with coherent activity (according to Fig. 7) . The numbers on the x axis represent tumors with coherent activity across the methods included in each plot. The plots represent the median contribution of signatures to the burden of coherent tumors (filled circles) and the interquartile range of the distribution (whiskers). In the stacked bar plots below each graph, the fraction of all tumors exposed to the treatment with coherent signature activity are colored, while the fraction of tumors with activity according to only one method or with incoherent activity are filled with diagonal lines. For example, the 318 colorectal tumors treated with the drug show activity of the capecitabine/5-FU signature according to either method. The activity given by both methods is coherent in 64% of them (204). b, Contribution in total number (upper) and proportion (lower) of all treatmentassociated SBS (left) and DBS (right) to the mutational burden of metastatic tumors. Only coherent tumors are included in these plots (numbers shown in parentheses). A separate column in the left graph presents the activity of cisplatin-associated signatures in ten metastatic samples of four pediatric patients with osteosarcoma (see Methods). different methods), the mutational toxicity of drugs measured in this study is resilient to these differences.
In our study, we used the mutational toxicity identified from samples of tumors exposed to these drugs as a proxy of their potential mutational effect across the healthy tissues of patients. The availability of biopsies from patients' metastatic tumors and the clonal expansion that is characteristic of tumor development provide a unique opportunity to identify drug-associated mutations ( Fig. 1a) . Although mutations can also accumulate in cells of healthy tissues, these samples are harder to obtain and the lack of clonal expansion would make treatment-associated mutations much more difficult to detect. Thus, the mutational risk calculated in this study may be regarded as a bulk estimate of the mutagenic potential of chemotherapies across healthy tissues. The mutational risk chemotherapies pose for various types of healthy cells from different tissues may differ due to differences in the rate of division, hierarchy and proficiency of DNA repair. These reasons and others, such as the pharmacodynamics and metabolization of drugs, probably also suggest that there is a differential risk between different tissues and individuals. The estimation of mutational toxicity thus needs to be refined through carefully planned prospective studies that periodically sample healthy cells (for example, blood cells) from treated patients and survivors to monitor across time the load of mutations introduced by chemotherapies.
Our estimate of the contribution of chemotherapies to the mutational burden of metastatic tumors according to time of exposure is conditional on the annotations collected with regard to the length of exposure to each treatment. Since inaccuracies and omissions may appear among such annotations, we also made these calculations using the average time of chemotherapy exposure as taken from clinical guidelines, and with a subset of patients where duration of treatment was not estimated by clinicians, but rather taken directly from patient charts. Overall and across all cases, we obtained similar mutational burden and toxicity values (Extended Data Fig. 10c-f ). In any case, our estimate focuses on the order of magnitude, and it is meant to be understood as such, of this contribution rather than on the actual number calculated.
Although tumors in the cohort were exposed to 206 different therapies (as part of complex treatment regimens), we only identified the mutational signatures of six widely used treatments. On the one hand, therapies that do not directly damage DNA or alter the pool of nucleotides are not expected to leave a mutational footprint. On the other, we chose to be conservative and other true associations may be found under the stringent limit of significance we set ( Supplementary Table 1 and Supplementary Data) . Moreover, the statistical power of this cohort may be insufficient to detect some associations. The approach developed in this study could be used to unravel previously unknown drug-associated mutational signatures in larger cohorts or cohorts undergoing specific treatments as they become available in the future.
In summary, in this study we present known as well as new mutational signatures associated with platinum-based drugs, confirm the role of defective DNA repair pathways in certain treatment-associated signatures and reveal the mutational footprint of capecitabine/5-FU. We use the contribution of treatment footprints to the TMB as a proxy of their contribution to mutations generated in the healthy cells of patients undergoing chemotherapy. This study provides a new window into the precise appraisal of the risk posed by chemotherapies to induce mutations in patients' tissues, that is, their mutational toxicity, which may cause late side effects, with special potential relevance for pediatric cancer survivors.
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Methods
Genomics and clinical data of tumor samples. SBS, DBS and indels, referred to collectively as mutations, detected in 3,506 metastatic tumor samples (including relapses) were obtained from the Hartwig Medical Foundation 15 (DR-024 v.2). We call this the metastatic adult cohort (or metastatic cohort, for short). We kept only mutations labeled as PASS by the calling pipeline and filtered out mutations in poorly mappable (Duke regions and CRG36mer) and low-complexity regions of the genome 40 . In parallel, clinical data of the donors of each sample were obtained from the same source. These data comprised the treatments administered to each patient in the cohort and the start and end dates of each treatment round. We then converted treatment regimen acronyms to their unitary drugs and manually assigned drugs administered to patients to 58 different FDA drug categories (https://www.accessdata.fda.gov/cder/ndctext.zip); the start and end dates of treatments were used to calculate the treatment period.
The SBS of 12 metastatic osteosarcoma samples from 4 pediatric patients were obtained from the St. Jude Cloud data resource (St. Jude cohort) and the information regarding treatment with cisplatin and its duration was retrieved from the metadata of a related publication 30 . The SBS were fitted 41 to the COSMIC mutational signatures v.3. In 10 of the samples from the 4 patients, we detected the activity of signatures 31 and 35 (cisplatin) and proceeded to calculate its contribution to the TMB. The exonic SBS and clinical data of one cohort of patients with glioblastoma (treated with TMZ), as well as annotations of the tumors that had undergone hypermethylation of the MGMT promoter were obtained from a previous publication 13 . For the analysis of mutations of TMZ-exposed tumors, we used a predefined list of MMR genes 42 to identify MMR-deficient tumors.
Extraction of mutational signatures active across tumor samples.
The extraction of the mutational signatures active in the tumor samples from the metastatic adult cohort was carried out with SignatureAnalyzer 16, 17 and SigProfiler 2, 18 to ensure that the conclusions of the study were not dependent on a specific signature extraction method. The two methods chosen to carry out the extraction are currently the standard in the field and they are based on different approaches. While SigProfiler approaches the solution by bootstrapping a gradient descent NMF iterative method, deciding the optimal number of latent signals based on ad hoc clustering criteria, SignatureAnalyzer automatically fits a generative probabilistic model, thereby allowing for automatic inference of the optimal number of signatures. The same choices were made in a previous effort to produce a comprehensive catalog of mutational signatures in human cancers 3 . To run SignatureAnalyzer, we used the R implementation provided by the authors of the method (https://www.synapse.or g/#!Synapse:syn11801488) 16, 17 . Because of the limitations in obtaining a MATLAB license to run the signature extraction with SigProfiler, we reimplemented the entire procedure in the Julia programming language 43 (available at https:// bitbucket.org/bbglab/sigprofilerjulia). We prepared the cohort of tumor samples for both methods as explained by their authors in the analysis of similar cohorts 3 . All details on the execution of the extraction methods and the comparison of their results are presented in the Supplementary Note.
For the sake of validation, we also extracted the signatures active across colorectal tumors using a third non-NMF-based signature extraction method 19 .
We present the results based on the SignatureAnalyzer extraction throughout the main figures of the article. Equivalent results based on the SigProfiler extraction are presented as Extended Data Figures.
To calculate the number of mutations contributed by different signatures (presented in Figs. 5 and 6), we selected those tumor samples for which both methods showed a minimum agreement, that is, their relative activities to the signature of interest, either treatment-or aging-related, differed by no more than 0.15. The relative activity or number of mutations represented in the figures for each signature is the mean of the values inferred from both methods. The results for all tumor samples based on each method are presented in the Extended Data Figures.
Dependencies between individual treatments and signature exposures.
To infer dependencies between the treatments administered to the patients and the exposures to the mutational signatures uncovered, we required two levels of analysis. First, for each treatment label T, we established which signatures were strongly associated with T (step 1) on adjustment for tumor type. Second, we ruled out treatment-signature associations that could be explained with higher parsimony by another concomitantly administered treatment (step 2).
To address step 1, we devised a logistic regression approach with the response variable Y representing whether T had been administered or not, and the design matrix given by the relative exposures of each sample to each signature. Specifically, if N is the number of samples and s is the number of signatures, let X be the design matrix of size N × (s + 1) defined by the column vectors of normalized exposures (z-scores) to each signature across all samples, also including an intercept column. We wanted to estimate β = (β 0 ,β 1 ,…,β s ) such that logit E Y j X ð Þ ¼ X  β I , that is, the basal effect β 0 (log odds) and the log odds ratios β 1 ,…,β s .
A straightforward logistic regression approach would face an important challenge in our setting: the treatments being administered to the patients show dependencies on tumor type. Since tumor type can also explain the exposure to tumor type-specific signatures, tumor type is a clear confounder, hence we needed to correct for it. To this end, we fitted an ensemble of logistic models to balanced, stratified random data samples. Specifically, we fitted an ensemble of 1,000 L2-regularized logistic regression models with a likelihood function of the form
and regularization strength λ = 10. Each logistic model was fitted with a randomized subset, balanced and stratified by tumor type, that is, for each tumor type the same number of treated and untreated samples were drawn. Thus, we required the same number n ¼ α  min t; u ð Þ I of treated and untreated samples to be drawn, where t (respectively, u) are the number of treated (respectively, untreated) samples per tumor type. The factor α was set to 1/3 as a compromise to prevent the same sample subgroups showing up in every randomization, while keeping each regression informative.
For each treatment and signature, we obtained a vector (β 1 ,…,β s ) arising from each randomization that allowed us to calculate an empirical P for each signature as the proportion of instances where values are negative over the 1,000 randomizations. We also assessed the effect size of each treatment-signature association as the average fold change of the exposures to the signature between treated and untreated samples. Finally, we deemed significant those treatmentsignature associations with an effect size > 2 and P < 0.001.
In step 2, we aimed to assess the signature-specific mutation rate that can be allocated to each treatment when several concomitant treatments co-occur. The first step produced a collection of putative treatment-signature associations. However, we reasoned that some of these associations might be artifacts explained by the fact that several treatments were administered to similar sets of patients, such that some treatments could 'borrow' the association from the true causal treatment.
Given a treatment T and a signature S, we were bound to estimate the relative contribution of T to the exposure of S compared to other concomitant treatments associated with S. To this end, we conducted a positive least squares regression, as follows: let N be the number of samples; let X be the N × 2 design matrix with binary values with columns corresponding to T and a concomitant treatment C; and let Y be the N-dimensional vector of exposure of target signature S. We wanted
. We can think of each β i as an 'average efficiency' to generate the exposure of signature S; likewise, we can think of β T /β C as the 'relative efficiency' of T with respect to C. Bearing in mind this setup, we can now analyze all the concomitant treatments of T and check in each case whether the estimated efficiencies support that T is the most efficient generator of the exposure of signature S. If the resulting efficiency of T is higher than all the other concomitant treatments associated with S, we can conclude that T is the treatment most probably associated with S.
Finally, we ran these steps with two treatment settings, coarse-and finegrained. The coarse-grained setting considers groups of treatments according to FDA category. The fine-grained setting considers specific treatment labels. For the sake of consistency, we deemed a treatment-signature association significant if either of the following conditions held: (1) both the specific treatment and its FDA group raise significance in the fine-grained and coarse-grained settings, respectively; (2) the specific treatment raises significance in the fine-grained setting, but no FDA group raises any significance in the coarse-grained setting.
Validation of the approach using synthetic datasets. We built synthetic datasets of mutations that are similar to the metastatic tumors analyzed with regard to the composition of mutational signatures. We then injected a known number of mutations drawn from the mutational profile of a foreign signature to a known number of samples of these synthetic datasets. Thus, we controlled the number of samples bearing the mutational footprint of the drug, the number of drug-induced mutations present in each sample, and the signature of the drug-induced mutations and the number of samples known to have undergone treatment (allowing for discrepancies between these two parameters). Using these synthetic datasets, we tested (1) the extraction of drug-associated signatures, (2) the detection of the mutational footprints of drugs through the regression ensemble, (3) the identification of the correct etiology of each signature in the case of tumors exposed to cotreatments and (4) the accuracy of the estimation of the number of mutations contributed by drugs to the TMB. In the analyses, we challenged our entire methodological setting with fluctuations in the synthetic data reflecting a variety of common scenarios. The analysis of these synthetic datasets demonstrated that the approach followed correctly identified the foreign signatures as the molecular footprints of anticancer treatments within a wide range of numbers of exposed samples. The methodology is robust to systematic errors such as missannotation of treatments or lack of activity of the associated signatures in a subset of exposed samples. It can also estimate the mutational burden contributed by the treatment within acceptable confidence intervals. The results of these analyses have been useful to fine-tune the parameters of the methodologies developed to detect the mutational footprint of treatments. Details of the methodology and results of the analysis with synthetic datasets can be found in the Supplementary Note.
Identification of mutational signatures active across other metastatic tumors.
Due to the low number of mutations in the glioblastoma cohort used in the analyses, rather than extracting mutational signatures de novo, we fitted the catalog of identified mutational signatures 7 to the mutational profile matrix of each sample of the cohort. We employed deconstructSigs v.1.8t 41 using the Pan Cancer Analysis of Whole Genomes SBS 3 as a reference signature.
Strand asymmetry of treatment-associated signatures. To calculate the strand asymmetry of signature activity, we used a slight modification of an approach described elsewhere 44 . Briefly, using pyrimidines as a base reference, we classified each of the mutations as occurring in either the transcribed or nontranscribed strands (or leading and lagging, for replication). We then retrieved the trinucleotide context, obtaining 96 channels for both transcribed and nontranscribed (leading and lagging, respectively) yielding 192 in total. The identity of the signatures extracted across the 192 channels (averaged) was assessed through their cosine similarity to the signatures extracted from the adult metastatic cohort across the 96 channels. We pooled the trinucleotide counts corresponding to each of the six pyrimidine base change channels (C>A through to T>G) and selected the channel with the largest contribution to the signature profile to represent it. Then, the activity of these channels in the transcribed and nontranscribed (leading and lagging) strands were calculated. Assuming the activity in the transcribed (leading) strand is S 1 and the activity in the nontranscribed (lagging) strand is S 2 , we calculated the strand asymmetry as (S 2 − S 1 )/(S 2 + S 1 ). This is the value plotted in Extended Data Fig. 2c .
Relationship between activity of treatment-associated signatures and duration of exposure.
We sorted metastatic tumor samples originated from each organ according to the duration of their exposure to different treatments. Then, for cohorts with >40 tumor samples with mutations associated with each treatment, we created two groups of samples, long and short exposure, containing the 25% of tumor samples with longer and shorter treatment duration, respectively. We obtained the number of mutations associated with treatment i in each tumor as M´X n j¼0 S ij where S ij for j = 1,…,n are the relative exposures of the tumor to the mutational signatures associated with treatment i, and M is the total mutation burden of the tumor. Finally, we compared the distribution of the burden of treatment-associated mutations of short and long exposure tumor samples using the Mann-Whitney U-test.
Timing and clonality of treatment-associated mutations. We used the MutationTime.R package (v.0.99) developed by Gerstung et al. 29 and tested across 2,658 primary tumor samples. This tool exploits large chromosomal amplifications and/or whole-genome duplication of a tumor to classify all its SBS as early, late or subclonal. The method classifies mutations in a tumor as clonal early, clonal late or subclonal. Then, we associated each mutation uniquely with a mutational signature using a maximum likelihood approach 45, 46 .
We calculated the fold change between the relative proportions of late and early clonal mutations associated to specific mutational signatures, such as the ones associated with platinum-based drugs or capecitabine/5-FU, as well as with other etiologies. We provided this fold change as (n 1 /N 1 )/(n 0 /N 0 ), where n 0 ,n 1 are the number of signature-associated mutations labeled clonal early and clonal late, respectively; N 0 ,N 1 are the total number of mutations labeled clonal early and clonal late, respectively.
Similarly, we calculated the fold change between the relative proportions of clonal (grouping early and late clonal mutations) and subclonal mutations associated to specific mutational signatures. We provided this fold change as
, where n s is the number of signature-associated mutations labeled subclonal and N s is the total number of subclonal mutations.
Risk of acquiring coding-affecting mutations through treatments.
For each cohort of tumor samples, we inferred the proportion of neutral mutations hitting coding nonsynonymous sites that could be explained by a group of etiologies. The attribution of the observed mutations to etiologies was carried out based on those signatures where we could establish an association with the etiology. The etiologies, alongside their corresponding SigProfiler signatures, are the following: capecitabine, E-SBS19; carboplatin, E-SBS1; cisplatin, E-SBS1; oxaliplatin, E-SBS20; tobacco-smoking, E-SBS17; aging, E-SBS23.
To conduct this analysis, we partitioned the sequence of the human genome into 1-Mb chunks. Nonmappable and repetitive positions were discarded. For the etiology and cohort of samples of interest, we considered all the mutations observed in each chunk, excluding those mutations in Cancer Gene Census genes 31 to avoid positive selection bias.
To model the local mutation rate explained by an etiology S across 1-Mb chunks, we relied on a generative probabilistic model whereby: (1) the probability that a new mutation occurs in a 1-Mb chunk is proportional to the average number of mutations in this chunk explained by S across samples; (2) the probability that a new mutation reaches a specific site with context c in the 1-Mb chunk is proportional to the normalized relative frequency of mutations in context c implied by signature S, that is, the relative frequency for context c assuming all reference trinucleotides had the same abundance.
From the signature deconstruction analysis, we inferred the function P S (c,i) encoding the probability that a mutation in context c and sample i has been generated by signature S. Given a chunk, say k, let n ci be the number of mutations in context c and sample i observed in the chunk. Then, the average number of mutations explained by S across the samples in chunk k is
If f c stands for the normalized relative frequency for channel c in signature S, we assigned all the per-mappable-site mutation probabilities of the chunk as follows: assuming n c is the count of mappable sites in context c, all the sites of the chunk in context c are given the same probability p c determined by the following two conditions: X c n c´pc ¼ 1 ð1Þ
Finally, using VEP 88 (ref. 32 ) we annotated the most severe consequence types for each genic (coding) mapping to each mappable site of the chunk. We then counted all possible nucleotide changes yielding mutations that potentially affected the sequence of coding genes, that is, nonsynonymous and truncating, for each context c in the chunk, letting m c be this count. Finally, we estimated the proportion of coding-affecting mutations among neutral mutations explained by S across all chunks as where k denotes the index of the chunks; we denote the specific counts and probabilities for each chunk with the (k) superscript. In summary, we obtained a site-specific neutral mutation rate explained by a given signature S first by using the observed mutations to define local mutation rates in 1-Mb chunks. Then, we spread a single mutation as site probabilities in accordance with the operative signature. Finally, we derived an expected overlap of a unit exposure with the coding-affecting region.
5-FU mutations in mutant strains of L. infantum.
Sequencing reads of five mutant strains of L. infantum resistant to treatment with 5-FU, and the parental sensitive strain 25 , were obtained from the European Nucleotide Archive database (European Molecular Biology Laboratory-European Bioinformatics Institute, secondary accession nos. ERP002415 and ERP001815, respectively). The five mutant strains had been treated with 5-FU before sequencing, while the parental strain was cultivated under the same conditions (except for the drug) and for the same duration. We downloaded the L. infantum reference genome from the Ensembl Genomes database and aligned the reads of both resistant and parental strains to its sequence, using Bowtie v.2.3.5 (ref. 47 ). As in the original publication reporting this dataset, the aligned reads were sorted and processed with SAMtools (v.1.9) 48 ; mutations were called for the parental and resistant strains. High-quality mutations (>20) were used to build the mutational profile (trinucleotide context changes) of each sequenced strain.
Significance of cosine similarity with regard to a signature. Given a mutational signature S (for example, SBS capecitabine) and a cosine similarity C (for example, 0.8), we can associate a P value to C relative to the signature S by randomly drawing the vector σ from the signature simplex and calculate the frequency with which cos S; σ ð Þ≥ C I . We carried out this calculation by randomly drawing 1,000 signatures with the same expected sparsity as found in the COSMIC catalog: first, a signature was chosen uniformly from the COSMIC catalog; then, a random permutation was applied on the channels.
Cosine similarity reconstruction. Given the three profiles S,C 1 ,C 2 , we found the weight parameter 0 < w < 1 that minimizes the cosine distance between the combination CðwÞ ¼ wC 1 þ ð1 � wÞC 2 I and S, that is, we maximized the objective function cos(S,C(w)) subject to the constraint 0 < w < 1.
Compilation and use of clinical guidelines. We compiled the clinical guidelines of treatment with a range of drug combination regimens for different tumor types. This compilation is presented as Supplementary Table 2 and contains details of the provenance of all guidelines listed. We then selected a duration of treatment within the interval contained in the guidelines for each drug and tumor type (taking into account all analyzed regimens). Selected durations (listed at the bottom of Extended Data Fig. 1 | Treatments administered to patients in the metastatic adult cohort. a, Left: distribution of time elapsed since earliest treatment administered to patients in the metastatic adult cohort. Right: Distribution of time elapsed since latest treatment administered to patients in the metastatic adult cohort. b, Left: exposure (binary Treated/Untreated) of tumors originated in different organs (rows labeled with color code introduced in Fig. 1 of the main paper) to drugs within different FDA classes (columns). The number of tumors exposed to each drug family are shown in Fig. 2a . Right: exposure (binary Treated/Untreated) of tumors originated in different organs (rows) to selected chemotherapies (columns). Fig. 2 | Treatment-associated signatures. a, Equivalent to Fig. 2c of the main paper for signatures extracted using SigProfiler. The Carboplatin/Cisplatin-associated and the Capecitabine/5-FU signatures appears very close to significance (p-value=0.002 and p-value=0.001, respectively) and has thus been "rescued" as associated with the treatment. b, Mutational profiles of SigProfiler-extracted SBS and DBS signatures associated to treatments. We show the cosine similarities of E-SBS1, E-SBS19, E-DBS5 against signatures SBS31, SBS17b and DBS5, respectively. c, Strand asymmetry of selected SignatureAnalyzer-extracted signatures. Each dot corresponds to a signature, with the abscissa representing its replication strand bias and the ordinate, the transcriptional strand bias. Note that strand bias is calculated taking as reference the channels in the mutational profile. Therefore, UV light-, tobacco and platinum-related drugs-induced mutations all show asymmetry with respect to transcription in the same direction, but appear positive or negative in the graph due to the specifically base that suffers each damage in the first place. Fig. 3 | comparison of treatment-associated signatures extracted with SigProfiler and SignatureAnalyzer. a, SignatureAnalyzer extracts four signatures for platinum based drugs, while SigProfiler extracts two. A linear combination of E-SBS21 and E-SBS25 extracted by SignatureAnalyzer and associated to Carboplatin and Cisplatin, yields a profile that is very similar to the signature associated with the same treatments extracted by SigProfiler (E-SBS1, cosine similarity 0.97). Similarly, a linear combination of E-SBS14 and E-SBS37, extracted by SignatureAnalyzer and associated to Cisplatin and Oxaliplatin, yields a similar profile to E-SBS20, extracted by SigProfiler and associated to Oxaliplatin (cosine similarity 0.85). b, A linear combination of E-DBS3 and E-DBS9, extracted by SignatureAnalyzer and associated to platinum based drugs, yields a very similar profile to E-DBS5, extracted by SigProfiler and associated to the same drugs (cosine similarity 0.99). c, The capecitabine-associated SBS signatures reconstructed by both methods are very similar (cosine similarity 0.99). d, Oxaliplatin-related and capecitabine-related signatures extracted from colorectal tumors using a not-NMF approach compared to homologous signatures extracted using SignatureAnalyzer. Both signatures possess virtually identical profiles to those extracted using SignatureAnalyzer. Fig. 4 | Mutational signatures associated to radiation and temozolomide. a, HR-deficiency plays a key role in the appearance of a short indel signature (SignatureAnalyzer-extracted) previously associated to radiation. Tumors in the top quartile of activity of HR signature (BRCAness signature) are considered HR-deficient, while tumors in the bottom quartile are deemed HR-proficient. The distribution of the number of short indels of this signature across HR-deficient and HR-proficient tumors either exposed or not exposed to radiation have been compared using a one-tailed Mann-Whitney test. b, MMR or MGMT-deficiency plays a key role in the generation of a TMZ-associated SBS signature. Left panel represents the load of TMZassociated SBS in tumors exposed or unexposed to TMZ separated by their MMR status (considered defective with at least one protein-affecting mutation in an MMR-related gene). Right panel represents the load of TMZ-related exonic SBS in recurrent glioblastomas in an independent cohort exposed or not exposed to TMZ. TMZ-treated, non-MMR-deficient tumours have been split into two groups based on the methylation status of the MGMT promoter. Fig. 7 | Selection of coherent tumors according to the activity of signatures attributed by both extraction methods. Left panels show the agreement of both methods in the attribution of the activity of treatment-associated signatures across tumors. Each pair of circles connected by a line represents the exposure attributed by both methods to a tumor. Red circles represent the activity attributed by SigProfiler, while blue circles represent the activity attributed by SignatureAnalyzer. Middle panels show the correlation (with Pearson's r) between the activity attributed by both methods to all tumors, while right panels present the correlation (with Pearson's r) of the activity attributed by both methods to coherent tumors (difference between relative activities lower than 0.15).
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Data analysis
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